Drug Profile
Linvoseltamab - Regeneron Pharmaceuticals
Alternative Names: BCMAxCD3 antibody - Regeneron Pharmaceuticals; REGN-5458Latest Information Update: 27 Apr 2024
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Multiple myeloma
- Phase II Smoldering multiple myeloma
- Phase I/II Transplant rejection
Most Recent Events
- 19 Apr 2024 Regeneron Pharmaceuticals plans a phase II trial for Multiple myeloma (Newly diagnosed) in USA (IV) (NCT06376526)
- 07 Apr 2024 Efficacy and adverse event data from the phase I/II LINKER-MM1 trial in Multiple myeloma released by Regeneron Pharmaceuticals
- 05 Mar 2024 Regeneron Pharmaceuticals plans a phase I/II LINKER-AL2 trial for Amyloid light-chain amyloidosis (Treatment-experienced) in April 2024 (Parenteral) (NCT06292780)